{"schema_version":"secwatch.filing_event.v1","accession":"0001437402-26-000012","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.083588+00:00","generated_at":"2026-05-16T01:42:01.815847+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher","bullets":["IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).","XPHOZAH revenue $103.6M in 2025; 2026 guidance $110-120M.","Total 2025 revenue $407.3M; net loss $61.6M ($0.26 loss per share).","Cash $264.7M at Dec 31, 2025; fully capitalised for current plans.","Phase 3 ACCEL trial for tenapanor in CIC dosed first patient; topline H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437402-26-000012","json":"https://secwatch.observer/filing/0001437402-26-000012.json","markdown":"https://secwatch.observer/filing/0001437402-26-000012.md","text":"https://secwatch.observer/filing/0001437402-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/0001437402-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/ardx-20260219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:42:01.815847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}